North Capital’s Charles River Laboratories CRL Stock Holding History

North Capital’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1	Closed	-$156	–	214
2025 Q3	$156	Buy	+1	New	+$159	﹤0.01%	663

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

North Capital's CRL Position: Q4 2025 in Review

North Capital sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 1 share — an estimated $156 sold.

North Capital first reported a position in CRL in Q3 2025 and held it in 1 quarter. The position peaked at $156 in Q3 2025. 582 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

North Capital reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
North Capital sold 1 Charles River Laboratories share in Q4 2025, an estimated $156.
North Capital first reported a position in Charles River Laboratories in Q3 2025 and held it in 1 quarter.
North Capital's Charles River Laboratories position peaked at $156 in Q3 2025.
582 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on North Capital's 13F filing for Q4 2025, filed 18 Feb 2026.